Semaglutide is a glucagon-like peptide-1 component, approved by the FDA as three brand-name medications, namely Ozempic, Wegovy and Rybelsus. It mimics a gut hormone that tells the brain the body is full, subsequently suppressing appetite and regulating blood sugar. Danish company Novo Nordisk's patent on semaglutide expired on March 20, paving way for Indian drugmakers to make cheaper versions.